Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/HK1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HK1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HK1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HK1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HK1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HK1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/HK1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/HK1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HK1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0030148 | Oral cavity | OSCC | sphingolipid biosynthetic process | 53/7305 | 103/18723 | 6.81e-03 | 2.53e-02 | 53 |
GO:00434107 | Oral cavity | OSCC | positive regulation of MAPK cascade | 213/7305 | 480/18723 | 8.71e-03 | 3.16e-02 | 213 |
GO:00442625 | Oral cavity | OSCC | cellular carbohydrate metabolic process | 130/7305 | 283/18723 | 9.98e-03 | 3.49e-02 | 130 |
GO:00616202 | Oral cavity | OSCC | glycolytic process through glucose-6-phosphate | 9/7305 | 12/18723 | 1.27e-02 | 4.24e-02 | 9 |
GO:2000303 | Oral cavity | OSCC | regulation of ceramide biosynthetic process | 9/7305 | 12/18723 | 1.27e-02 | 4.24e-02 | 9 |
GO:00027022 | Oral cavity | OSCC | positive regulation of production of molecular mediator of immune response | 58/7305 | 117/18723 | 1.28e-02 | 4.27e-02 | 58 |
GO:0051785 | Oral cavity | OSCC | positive regulation of nuclear division | 31/7305 | 57/18723 | 1.32e-02 | 4.38e-02 | 31 |
GO:00507643 | Oral cavity | OSCC | regulation of phagocytosis | 48/7305 | 95/18723 | 1.47e-02 | 4.77e-02 | 48 |
GO:0006979110 | Oral cavity | LP | response to oxidative stress | 181/4623 | 446/18723 | 5.74e-14 | 6.10e-12 | 181 |
GO:1903320110 | Oral cavity | LP | regulation of protein modification by small protein conjugation or removal | 111/4623 | 242/18723 | 4.81e-13 | 4.30e-11 | 111 |
GO:001605013 | Oral cavity | LP | vesicle organization | 128/4623 | 300/18723 | 4.96e-12 | 3.98e-10 | 128 |
GO:0031396110 | Oral cavity | LP | regulation of protein ubiquitination | 95/4623 | 210/18723 | 5.88e-11 | 3.61e-09 | 95 |
GO:0000302110 | Oral cavity | LP | response to reactive oxygen species | 95/4623 | 222/18723 | 2.23e-09 | 9.98e-08 | 95 |
GO:0042542110 | Oral cavity | LP | response to hydrogen peroxide | 68/4623 | 146/18723 | 6.95e-09 | 2.81e-07 | 68 |
GO:0062197110 | Oral cavity | LP | cellular response to chemical stress | 130/4623 | 337/18723 | 8.94e-09 | 3.52e-07 | 130 |
GO:000734614 | Oral cavity | LP | regulation of mitotic cell cycle | 163/4623 | 457/18723 | 7.64e-08 | 2.56e-06 | 163 |
GO:0034599110 | Oral cavity | LP | cellular response to oxidative stress | 110/4623 | 288/18723 | 2.19e-07 | 6.65e-06 | 110 |
GO:004354312 | Oral cavity | LP | protein acylation | 93/4623 | 243/18723 | 1.65e-06 | 3.86e-05 | 93 |
GO:014001413 | Oral cavity | LP | mitotic nuclear division | 106/4623 | 287/18723 | 2.29e-06 | 5.10e-05 | 106 |
GO:000647312 | Oral cavity | LP | protein acetylation | 78/4623 | 201/18723 | 6.06e-06 | 1.20e-04 | 78 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HK1 | SNV | Missense_Mutation | novel | c.862G>A | p.Gly288Arg | p.G288R | P19367 | protein_coding | tolerated(0.21) | probably_damaging(0.982) | TCGA-A7-A4SC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
HK1 | SNV | Missense_Mutation | | c.100C>T | p.Arg34Trp | p.R34W | P19367 | protein_coding | deleterious(0.03) | probably_damaging(0.979) | TCGA-A7-A6VV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
HK1 | SNV | Missense_Mutation | novel | c.2692N>C | p.Glu898Gln | p.E898Q | P19367 | protein_coding | deleterious(0.01) | probably_damaging(0.958) | TCGA-D8-A4Z1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
HK1 | deletion | Frame_Shift_Del | novel | c.797delG | p.Gly266GlufsTer9 | p.G266Efs*9 | P19367 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
HK1 | SNV | Missense_Mutation | rs747689299 | c.1414C>T | p.Arg472Trp | p.R472W | P19367 | protein_coding | deleterious(0.01) | probably_damaging(0.945) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HK1 | SNV | Missense_Mutation | rs867948527 | c.2740C>T | p.Arg914Trp | p.R914W | P19367 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HK1 | SNV | Missense_Mutation | novel | c.703G>A | p.Gly235Ser | p.G235S | P19367 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HK1 | SNV | Missense_Mutation | rs146727978 | c.2548N>T | p.Arg850Cys | p.R850C | P19367 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HK1 | SNV | Missense_Mutation | novel | c.1492G>A | p.Glu498Lys | p.E498K | P19367 | protein_coding | deleterious(0.01) | probably_damaging(0.975) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HK1 | SNV | Missense_Mutation | novel | c.932G>A | p.Arg311Gln | p.R311Q | P19367 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |